<DOC>
	<DOCNO>NCT00417222</DOCNO>
	<brief_summary>The purpose study investigate whether angiotensin II receptor blocker ( olmesartan ) , addition conventional treatment , reduce mortality morbidity hypertensive patient stable chronic heart failure .</brief_summary>
	<brief_title>Supplemental Benefit Angiotensin Receptor Blocker Hypertensive Patients With Stable Heart Failure Using Olmesartan</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Patients meet following criterion . Patients NYHA class II IV chronic heart failure . Patients history hypertension antihypertensive medication . Patients age 20 year old less 80 year entry . Stable patient angiotensin convert enzyme inhibitor and/or betablocker . Patients angiotensin II receptor blocker . Patients renal dysfunction ( serum creatinine &gt; =3.0mg/dL ) receive chronic hemodialysis . History drug hypersensitivity olmesartan . Patients severe liver dysfunction . History angioedema . History malignant tumor lifethreatening illness poor prognosis . Pregnant possibly pregnant patient . Cardiovascular surgery within 6months prior date entry . Acute myocardial infarction within 6 month prior date entry . Percutaneous coronary intervention stent implantation within 6 month prior date entry . Other patient deem unsuitable subject study treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>